Matthew Clark, CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL platforms, and several service providers […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!